In 2020, right before the COVID pandemic really got going, @CarlJune and I debated #Cell #immunothewrapy vs #bispecific #TcellEngagers. I think many of the points we discussed and debated will play out over the next few years. Powerful technologies that are already helping cancer patients, but also will benefit from a great deal of additional development.